LLY

1,076.96

+0.06%↑

JNJ

207.49

-0.14%↓

ABBV

230.16

+0.01%↑

UNH

331.59

+1.17%↑

AZN

92.89

+0.42%↑

LLY

1,076.96

+0.06%↑

JNJ

207.49

-0.14%↓

ABBV

230.16

+0.01%↑

UNH

331.59

+1.17%↑

AZN

92.89

+0.42%↑

LLY

1,076.96

+0.06%↑

JNJ

207.49

-0.14%↓

ABBV

230.16

+0.01%↑

UNH

331.59

+1.17%↑

AZN

92.89

+0.42%↑

LLY

1,076.96

+0.06%↑

JNJ

207.49

-0.14%↓

ABBV

230.16

+0.01%↑

UNH

331.59

+1.17%↑

AZN

92.89

+0.42%↑

LLY

1,076.96

+0.06%↑

JNJ

207.49

-0.14%↓

ABBV

230.16

+0.01%↑

UNH

331.59

+1.17%↑

AZN

92.89

+0.42%↑

Inicio・Lista de Acciones・Fate Therapeutics Inc

Fate Therapeutics Inc

Cerrado

SectorSanidad

1 -0.99

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

Máximo

1.01

Métricas clave
By Trading Economics
Ingresos	1.8M -32M
Ventas	-166K 1.7M
BPA	-0.27
Margen de beneficios	-1,852.384
Empleados	181
EBITDA	7.9M -29M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+400% upside

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-4.6M 121M
Apertura anterior	1.99
Cierre anterior	1

Noticias sobre sentimiento de mercado

By Acuity

55%

45%

305 / 374 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

0.9101 / 1.14 Soporte y Resistencia

Fate Therapeutics Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

24 dic 2025, 21:41 UTC

Adquisiciones, fusiones, absorciones

Nvidia to Buy Chip-Designer Groq for $20 Billion, CNBC Reports

26 dic 2025, 20:22 UTC

Charlas de Mercado

Oil Loses Ground On Russia-Ukraine Peace Efforts -- Market Talk

26 dic 2025, 20:13 UTC

Charlas de Mercado

U.S. Natural Gas Gains on Colder Weather Outlook -- Market Talk

26 dic 2025, 19:24 UTC

Adquisiciones, fusiones, absorciones

Nvidia's Groq Deal Is an Instagram Moment -- With 1 Big Risk -- Barrons.com

26 dic 2025, 17:45 UTC

Charlas de Mercado

U.S. Diesel Down on Lower Crude Prices, Freight-Sector Lull -- Market Talk

26 dic 2025, 15:52 UTC

Charlas de Mercado

Oil Futures Turn Lower After Steady Start -- Market Talk

26 dic 2025, 14:58 UTC

Charlas de Mercado

Silver, Gold Reach New Highs Amid Geopolitical Tension -- Market Talk

26 dic 2025, 14:41 UTC

Charlas de Mercado

U.S. Natural Gas Futures Look to End Week Higher -- Market Talk

26 dic 2025, 14:28 UTC

Charlas de Mercado

Dollar Indexes Flat as Yen Rally Wanes -- Market Talk

26 dic 2025, 13:47 UTC

Charlas de Mercado

Oil Futures Steady in Thin Holiday Trade -- Market Talk

26 dic 2025, 07:22 UTC

Charlas de Mercado

Comex Gold Futures' Strong Bullish Momentum in Play, Chart Shows -- Market Talk

26 dic 2025, 05:03 UTC

Charlas de Mercado

Malaysian Ringgit Likely to Face Pressure From Dollar Strength in 1Q -- Market Talk

26 dic 2025, 03:38 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

26 dic 2025, 03:38 UTC

Charlas de Mercado

Korean Won Strengthens, Supported by Verbal Interventions -- Market Talk

26 dic 2025, 02:44 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

26 dic 2025, 02:44 UTC

Charlas de Mercado

Singapore Dollar Weakens Slightly on Likely Position Adjustments -- Market Talk

26 dic 2025, 01:39 UTC

Charlas de Mercado

China's Central Bank Signals Possibility of Easing Policy in Coming Months -- Market Talk

26 dic 2025, 01:14 UTC

Charlas de Mercado

Oil Edges Higher Amid Geopolitical Tensions -- Market Talk

26 dic 2025, 00:34 UTC

Charlas de Mercado

Yen Mostly Weakens Amid Risk-on Sentiment -- Market Talk

26 dic 2025, 00:15 UTC

Charlas de Mercado

Nikkei Gains 0.6%, Led by Tech, Videogame Stocks -- Market Talk

25 dic 2025, 23:42 UTC

Charlas de Mercado

Nikkei May Trade in Range; Yen in Focus -- Market Talk

25 dic 2025, 23:40 UTC

Charlas de Mercado

Gold Edges Higher Amid Geopolitical Risks -- Market Talk

25 dic 2025, 00:20 UTC

Adquisiciones, fusiones, absorciones

Nike Climb Boosts Dow, S&P 500 -- 2nd Update

24 dic 2025, 22:22 UTC

Adquisiciones, fusiones, absorciones

Nvidia, Groq Strike AI Tech Licensing Deal -- Barrons.com

24 dic 2025, 21:26 UTC

Adquisiciones, fusiones, absorciones

Nvidia to Buy Chip-Designer Groq for $20B, CNBC Reports

24 dic 2025, 19:35 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

24 dic 2025, 19:35 UTC

Charlas de Mercado

Treasury Yields Decline Ahead of Christmas -- Market Talk

24 dic 2025, 19:09 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Global Equities Roundup: Market Talk

24 dic 2025, 19:09 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

ServiceNow's Armis Acquisition Shouldn't Fuel Fears That Seat-Based Model Threatened -- Market Talk

24 dic 2025, 19:06 UTC

Charlas de Mercado

Oil Futures Little Changed in Light Pre-Holiday Trade -- Market Talk

Comparación entre iguales

Cambio de precio

Fate Therapeutics Inc previsión

Precio Objetivo

By TipRanks

400% repunte

Estimación a 12 Meses

Media 5 USD 400%

Máximo 8 USD

Mínimo 2 USD

De acuerdo con 8 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Fate Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

8 ratings

Comprar

Mantener

Vender

De acuerdo con 8 analistas que ofrecen calificaciones bursátiles a para Fate Therapeutics Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

0.9101 / 1.14Soporte y Resistencia

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentimiento

By Acuity

305 / 374 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.